The efficacy of bortezomib in human multiple myeloma cells is enhanced by combination with omega-3 fatty acids DHA and EPA: Timing is essential

Background & aimsAlthough bortezomib as one of the first line medicines that has greatly improved overall survival patients with multiple myeloma (MM), undesired drug resistance is frequently observed. Docosahexaenoic acid (DHA) and eicosapentaenoic (EPA) have been shown to be able enhance efficacy chemotherapeutic drugs in many cancer types. The aim present study was further evaluate anticancer activity DHA EPA relation chemosensitivity human MM cells. potential involvement NF-?B signaling pathway studied.MethodsMM cells were treated DHA/EPA or without bortezomib. Cell viability estimated by WST-1 assay. Apoptotic determined through flow cytometry using annexin V propidium iodide (PI) staining. Protein expression phosphorylation investigated western blotting.ResultsCell type dependent observed cell induced apoptosis L363, OPM2, MM.1S U266 lines both mitochondrial death receptor pathways. Treating significantly downregulated I?B? upregulated p65, indicating they triggered activation prior enhanced death. However, concomitant use combination either decreased bortezomib, timing coincubation important for effects on chemosensitivity.ConclusionsThe provides novel evidence EPA, highlights their rational utilization achieve therapeutic outcome MM. Although studied. blotting. chemosensitivity.